long intergenic non-protein coding RNA 1205Genealiases: []
Q-omics provides the consensus-scored LINC01205 profile across patient tissues and cancer cell-line models. LINC01205 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01205 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, LINC01205 RNA expression shows 6,606 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, THCA, and STAD as cancer lineages where LINC01205 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01205 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01205 survival associations across molecular data types. LINC01205 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01205 RNA expression–survival associations across cancer types. High LINC01205 expression shows unfavorable associations in MESO, ACC, UVM and KIRC, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01205 RNA expression.
This table summarizes LINC01205 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01205. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01205 shows lower tumor expression in THCA and CHOL and higher tumor expression in LUSC and ESCA. The THCA box plot shows higher LINC01205 RNA expression in normal versus tumor tissue (log2 FC = −0.015, t-test p = .022).
This table shows molecular features associated with LINC01205 in patient tissues and cancer cell lines. In patient samples, LINC01205 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01205 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma.
